Trial intelligence / Profile preview

ITCA 650 in Type 2 Diabetes (FREEDOM-CV)

NCT01455896Phase 3Completed

Sponsor
Intarcia Therapeutics
Start
Mar 2013
Primary completion
Mar 2016
Countries
9
01

Overview

A Phase 3 trial of ITCA 650 in type 2 diabetes mellitus (T2DM), sponsored by Intarcia Therapeutics. Started Mar 2013; status: completed.

02

Drugs

ITCA 650
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on NCT01455896.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01455896.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call